Результати пошуку - Mei Elsayed
- Показ 1 - 3 результатів із 3
-
1
Therapeutic Sequencing in ALK+ NSCLC за авторством Mei Elsayed, Petros Christopoulos
Опубліковано 2021Revisão -
2
<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non‐small c... за авторством Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J.F. Herth, Claus Peter Heußel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Arne Warth, Helge Bischoff, Peter Schirmacher, Albrecht Stenzinger, Michael Thomas
Опубліковано 2018Artigo -
3
Identification of a highly lethal V3<sup>+</sup>TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma за авторством Petros Christopoulos, Martina Kirchner, Farastuk Bozorgmehr, Volker Endris, Mei Elsayed, Jan Budczies, Jonas Ristau, Roland Penzel, Felix J.F. Herth, Claus Peter Heußel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Felix Lasitschka, Helge Bischoff, Rocı́o Sotillo, Peter Schirmacher, Michael Thomas, Albrecht Stenzinger
Опубліковано 2018Artigo
Інструменти для пошуку:
Пов'язані теми
Anaplastic lymphoma kinase
Internal medicine
Lung cancer
Malignant pleural effusion
Medicine
Oncology
ALK inhibitor
Adenocarcinoma
Cancer
Gastroenterology
Alectinib
Cancer research
Chemotherapy
Clinical trial
Colorectal cancer
Confidence interval
Crizotinib
Hazard ratio
KRAS
Progression-free survival
Progressive disease
ROS1
Radiation therapy
Receptor
Response Evaluation Criteria in Solid Tumors
Targeted therapy
Tyrosine kinase
Tyrosine-kinase inhibitor